Voyager Therapeutics, Inc.
NASDAQ:VYGRBiotechnology
+$0.09 today
- Market cap
- $103.92M
- Beta
- 1.25
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.96
Volume 0.84M
Average 0.54M
VYGR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Voyager Therapeutics, Inc.NASDAQ: VYGR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $24.6M fell 22.0% year over year, behind the -3.1% change in trailing-twelve-month research & development. Sequentially, it fell 31.6% from the prior quarter. Over 3 fiscal years it compounded at +30.4% a year.
Context
- Research & development amounted to 333.6% of revenue in FY2025, up 174.4 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -22.0% toward the trailing-twelve-month pace of -3.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 134.67M USD
- Year-over-year change
- +5.7%
- 4-year CAGR
- +16.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 134.67M | +5.7% |
| FY2024 | 2024-12-31 | 127.37M | +38.2% |
| FY2023 | 2023-12-31 | 92.17M | +51.7% |
| FY2022 | 2022-12-31 | 60.76M | -17.6% |
| FY2021 | 2021-12-31 | 73.79M | — |
Research & Development vs competitors
How VYGR compares with its peers on the latest reported figures
- VYGR's LTM Mar 2026 research & development of $127.75M is the 4th highest of the 11 companies compared; the peer median is $94.78M.
- Its year-over-year change of -3.1% is the 5th highest of 11, against a peer median of -16.1%.
- Research & development amounts to 350.1% of revenue for VYGR, versus a peer median of 383.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $159.57M | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $143.25M | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $129.09M | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $127.75M | -3.1% | +30.4% | 350.1% | |
| LTM Mar 2026 | $101.99M | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $98.25M | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $76.25M | +21.5% | -5.1% | 550.2% | |
| LTM Mar 2026 | $73.35M | -11.4% | +3.1% | 3638.2% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $30.71M | -36.7% | +16.2% | — |
| LTM Mar 2026 | $19.19M | -29.2% | -8.6% | — | |
| Peer median (excluding VYGR) | $94.78M | -16.1% | -1.0% | 383.4% | |
Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.42M | 40.91M | 250.01M | 80M | 40.37M |
| Cost of Revenue | 73.79M | 55.76M | 92.17M | 0 | 0 |
| Gross Profit | (36.37M) | (14.86M) | 157.84M | 80M | 40.37M |
| Gross Margin | -97.2% | -36.3% | 63.1% | 100.0% | 100.0% |
| Research & Development | 73.79M | 60.76M | 92.17M | 127.37M | 134.67M |
| Selling, General & Admin | 37.25M | 30.98M | 35.82M | 35.92M | 37.54M |
| Operating Expenses | 37.25M | 35.98M | 35.82M | 163.29M | 172.22M |
| Depreciation & Amortization | 5.17M | 6.19M | 4.44M | 4.73M | 4.06M |
| EBITDA | (66.03M) | (39.65M) | 138.18M | (59.61M) | (115.52M) |
| EBITDA Margin | -176.5% | -96.9% | 55.3% | -74.5% | -286.1% |
| Operating Income | (73.62M) | (50.84M) | 122.01M | (83.29M) | (131.84M) |
| Operating Margin | -196.8% | -124.3% | 48.8% | -104.1% | -326.6% |
| Interest Income | 0 | 1.79M | 11.72M | 18.33M | 10.62M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.42M | 4.45M | 11.72M | 18.95M | 12.27M |
| Income Before Tax | (71.2M) | (46.39M) | 133.74M | (64.34M) | (119.58M) |
| Pre-Tax Margin | -190.3% | -113.4% | 53.5% | -80.4% | -296.2% |
| Income Tax Expense | 0 | 16K | 1.41M | 665K | 144K |
| Net Income | (71.2M) | (46.41M) | 132.33M | (65M) | (119.72M) |
| Net Margin | -190.3% | -113.4% | 52.9% | -81.3% | -296.5% |
| EPS (Basic) | (1.75) | (1.21) | 3.08 | (1.13) | (2.04) |
| EPS (Diluted) | (1.75) | (1.21) | 2.97 | (1.13) | (2.04) |
| Weighted Avg Shares | 37.67M | 38.36M | 43.02M | 57.67M | 58.69M |
| Weighted Avg Shares (Diluted) | 37.67M | 38.36M | 44.57M | 57.67M | 58.69M |
Voyager Therapeutics, Inc.
NASDAQ:VYGR
Intrinsic Alpha fair value
Locked
Current Price
$1.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.